Nakatani, Fumihiko <br/><br/>
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy.  [electronic resource] 

 -  The Journal of pathology  Apr 2012 
 - 796-805 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-9896 
<br/><br/><label>Standard No.: </label>10.1002/path.3007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Biomarkers, Tumor--metabolism<br/>Bone Neoplasms--drug therapy<br/>Cell Line, Tumor<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Doxorubicin--pharmacology<br/>Drug Resistance, Neoplasm--genetics<br/>Drug Synergism<br/>Humans<br/>Imidazoles--pharmacology<br/>In Situ Hybridization<br/>Inhibitory Concentration 50<br/>Kaplan-Meier Estimate<br/>MicroRNAs--metabolism<br/>Multivariate Analysis<br/>Oligonucleotide Array Sequence Analysis<br/>Paraffin Embedding<br/>Piperazines--pharmacology<br/>Proportional Hazards Models<br/>Real-Time Polymerase Chain Reaction<br/>Reproducibility of Results<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Sarcoma, Ewing--drug therapy<br/>Time Factors<br/>Transfection<br/>Treatment Outcome<br/>Tumor Suppressor Protein p53--genetics<br/>Vincristine--pharmacology